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Background and purpose: Studies in women with epilepsy (WWE) regarding
pregnancy and labour complications have disclosed contradictory results. Our
purpose was to investigate whether WWE have a higher risk of acute cae-
sarean section (CS) or pregnancy complications than women without epilepsy
or women with other chronic diseases and, if we found a higher risk, to
explore potential explanations.
Methods: The study used prospectively registered obstetric data from the
Oppland Perinatal Database in the period 2001–2011, containing information
on 18 244 births, including 110 singleton pregnancies in mothers with vali-
dated epilepsy. Data regarding epilepsy were collected retrospectively from
medical records.
Results: Epilepsy was a significant risk factor for acute CS, breech presenta-
tion and low birth weight in offspring [odds ratio (OR), 1.93, 95% confidence
interval (CI), 1.2–3.1; OR, 2.29, 95% CI, 1.2–4.6 and OR, 2.10, 95% CI, 1.0–
4.2, respectively]. In multivariate logistic regression analysis, antiepileptic drug
exposure was an independent risk factor for acute CS (OR, 2.00; 95% CI,
1.06–3.77) and polytherapy was a significant risk factor for breech presenta-
tion (OR, 5.37; 95% CI, 1.13–25.57). Seizure frequency during pregnancy had
no influence on the complication rate.
Conclusions: We found that WWE using antiepileptic drugs during pregnancy
had increased rates of acute CS, breech presentation and low birth weight,
and that seizure frequency during pregnancy did not influence the complica-
tion rate.
Introduction
Previous studies have shown increased occurrence of
complications related to pregnancy and labour in
women with epilepsy (WWE), but results have been
contradictory [1–5]. The American Academy of Neu-
rology and American Epilepsy Society’s practice
parameter update [3] concluded that WWE using
antiepileptic drugs (AEDs) probably did not have a
substantially increased risk of caesarean section (CS).
A recent meta-analysis concluded that epilepsy
together with AEDs was associated with increased risk
of CS, labour induction, pre-term birth, haemorrhage
and foetal growth restriction [2]. A Swedish study
concluded that epilepsy was associated with increased
risks of several adverse outcomes, but AEDs did not
increase the risk [5].
Caesarean section, in particular acute CS, is associ-
ated with an increased health-related risk to both
mother and child [6–8]. A study from Norway reported
an increased rate of acute CS among WWE [9].
Explanatory factors were not investigated, but
increased foetal stress during delivery was suggested.
Between 30% and 40% of WWE experience seizures
during pregnancy [10,11]. Data from the EURAP reg-
istry (International Registry of AEDs and Pregnancy)
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reported poorer seizure control in 16% of pregnancies
in the second and third trimesters relative to the first tri-
mester [11]. Further assessments concerning pregnancy
outcomes and their associations with seizure control,
use of individual AEDs and pregnancy complications
have been recommended in a meta-analysis [2].
The aim of this study was to use a prospective
obstetric database to investigate whether the risk of
acute CS and pregnancy complications differed
between WWE, healthy women and women with other
chronic diseases. If we found an increased risk, a sec-
ond aim was to estimate the possible effect of AED
exposure and seizure frequency during pregnancy.
Materials and methods
The Oppland Perinatal Database contains prospec-
tively collected data from almost 95% of all com-
pleted pregnancies in Oppland County (189 000
inhabitants), Norway, between 1989 and 2012. In
Oppland County, there are two delivery hospitals with
obstetricians, midwives and anaesthesiologists on duty
at all times. Inclusion into the Oppland Perinatal
Database was initiated at first contact with one of the
two obstetric departments within the county. Medical
history, smoking habits, maternal age and parity were
registered at start of pregnancy in the compulsory
outpatient pregnancy record. Epilepsy data (AED
treatment and epileptic seizures) were collected retro-
spectively based on the woman’s medical record.
The current study included 18 244 births from 2001
to 2011 (prospective collection stopped in 2012 and
last collected data were only ‘raw data’ when the cur-
rent study was commenced and therefore not included
in analysis). The study was approved by the Regional
Ethical Committee.
Outcome variables
The twofold outcome variables, pregnancy and obstet-
ric complications, were selected based on results from
earlier studies [1–5] and information recorded in the
Oppland Perinatal Database.
Pregnancy complications
Pregnancy complications were gestational diabetes,
pre-term birth, pre-eclampsia, poly- or oligohydram-
nios and vaginal bleeding.
Obstetric complications
Obstetric complications were delivery by acute or
planned CS, breech presentation, induction of labour,
pre-term birth and birth weight <2500 g. According to
Scandinavian literature and clinical practice, a ‘planned’
CS is decided a minimum of 8 h before it is conducted,
whereas acute CS is conducted within 8 h after decision.
Acute CSs are subdivided into different urgency cate-
gories [12,13]. Cases with acute CS and epilepsy were
studied with regard to indication for acute intervention.
Breech presentation was included in the analysis as it is
associated with pre-term birth, obstetric risk factors and
CS [14,15]. Pre-term birth was defined, according to
international definitions, as a live baby born in the term
of gestation from the complete 22nd week to the com-
plete 37th week of gestation (154–258 days).
Exposure variables
The exposure variable was active, non-resolved epi-
lepsy. Subgroup exposure variables were AED treat-
ment for epilepsy and seizures.
Predictors
Selection of possible predictors for complications was
based on clinical experience and previous studies [1–
8,16–18]. They included smoking habits, pre-term
birth and overweight/obesity [World Health Organiza-
tion definition: body mass index (BMI) >25 kg/m2],
underweight (World Health Organization definition:
BMI < 18) previous CS, parity (primipara; first born)
and maternal age.
Study groups
We defined two main study groups, i.e. the epilepsy
group and healthy group (women without registered
chronic diseases). The validation procedure of epilepsy
is described elsewhere [19,20]. The frequency of epi-
lepsy was 0.60%. Epilepsy was defined according to
the International League Against Epilepsy [21] (epi-
lepsy is considered to be resolved for individuals with
age-dependent epilepsy syndrome who are past the
applicable age or those who have remained seizure-
free for the last 10 years, with no seizure medicines
for the last 5 years). Thus, 110 singleton pregnancies
in women with active, non-resolved epilepsy were
included in the epilepsy group, including 17 women
not treated with AEDs (five with seizures within the
last 10 years and 12 with AED use during the last
5 years). A total of 70 pregnancies in women with
resolved epilepsy were included in the healthy group
(n = 16 783). Subgroups were defined with regard to
AED types and registered chronic disease (Fig. 1).
Eight pregnancies in six women using AEDs for indi-
cations other than epilepsy (anxiety, bipolar disorder
and trigeminal neuralgia) were excluded from analysis.
Sample characteristics
A total of 97% of WWE had a minimum of two
appointments with a neurologist or epilepsy nurse
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during pregnancy. Seizures, medication and AED
doses were considered. Three WWE had only one or
no neurology consultation. At the start of pregnancy,
WWE were more often smokers (Table 1) and BMI
was lower compared with the chronic disease group.
There were no significant differences regarding sample
within the epilepsy group. The most commonly used
AEDs in monotherapy were lamotrigine [n = 23, mean
dose 278 (range 50–600) mg], carbamazepine [n = 25,
mean dose 643 (range 200–1600) mg] and valproate
[n = 20, mean dose 784 (range 300–1500) mg]. AED
polytherapy was used in 12 pregnancies. Dosage
changes are routinely registered in medical records in
our department. No note regarding dosage change
means stable, unchanged medication. Dosage increases
were most often registered in the lamotrigine group,
in eight out of nine cases due to low serum level and
in one case due to seizures. Valproate was increased
in four cases due to seizures and in two cases due to
pregnancy. Carbamazepine was increased in two cases
due to seizure and reduced in two cases due to preg-
nancy.
Epileptic seizures during pregnancy were most com-
mon among those using polytherapy (58%). Seizures
were registered in 23 of the 93 WWE using AEDs
(25%). Tonic-clonic seizures with or without focal
onset accounted for 49%, focal seizures with and with-
out reduced awareness accounted for 29% and myo-
clonic, absence or unclassifiable seizures accounted for
22%.
Statistical analysis
Possible group differences in characteristics and fre-
quencies of complications and outcomes were tested
using the Pearson’s chi-squared test and an indepen-
dent two-sample t-test for categorical and continuous
data, respectively. BMI was, as the only factor, non-
normally distributed. Because of the large sample size
we chose to apply the two-sample t-test, due to the
central limit theorem and as the Mann–Whitney test
is strongly influenced by large sample size and large
number of ties. The groups were compared for base-
line characteristics and frequency of pregnancy-
related and obstetric complications. Based on results
from the frequency analysis, the outcome variables
acute CS and breech presentation were tested sepa-
rately in bivariate logistic regression analyses. Poten-
tial confounding factors were included in the
multivariate logistic regression analysis by including
factors that were significant at the 15% level in the
bivariate model into the multivariate model according
to Hosmer’s step-down procedure [22]. The level of
0.15 was chosen to ensure that weak, but still impor-
tant, predictors were included. Only presumed inde-
pendent factors were included. Results are given as
odds ratio (OR) with the corresponding 95% confi-
dence interval (CI) and P values. All tests were two-
sided and levels of significance were set to 5% (0.05)
unless otherwise stated. Statistical analyses were per-
formed using SPSS 23 (released 2015; IBM SPSS
Figure 1 Flow-chart of groups and subgroups used in this study from the Oppland Perinatal Database (OPD). *Active epilepsy: lam-
otrigine (n = 23), valproate (n = 20), carbamazepine (n = 25), other monotherapy (n = 13), polytherapy (n = 12), not using antiepileptic
drug (AED) (n = 17) not using antiepileptic drugs (n = 17). †Kidney (n = 76), heart (n = 98), rheumatism (n = 90), cancer (n = 37),
thyroid (n = 345), hepatitis/human immunodeficiency virus (n = 107), migraine (n = 173), other (n = 419).
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Statistics for Windows, Version 23.0; IBM Corp.,
Armonk, NY, USA).
Results
The frequency of acute CS, breech presentation and
low birth weight was significantly higher among
WWE than the healthy reference group (Table 2).
Acute caesarean section
Epilepsy was a significant predictor for acute CS (OR,
1.93; 95% CI, 1.19–3.14) in bivariate logistic regres-
sion analyses. Usage of AEDs, and lamotrigine in par-
ticular, was a significant predictor in subgroup
analysis (OR, 2.23; 95% CI, 1.34–3.70 and OR, 3.07;
95% CI, 1.21–7.79, respectively, Table 3). Seizures
during pregnancy did not predict acute CS. AEDs
predicted acute CS in multivariate logistic regression
analysis controlling for the pre-defined predictors
(OR, 2.00; 95% CI, 1.06–3.77; Table 3). Lamotrigine
had the highest odds for acute CS and cancer second
highest odds in bivariate subgroup analysis within the
group of chronic disease (OR, 3.00; 95% CI, 1.18–
7.61 and OR, 2.73; 95% CI, 1.29–6.21, respectively;
data not shown).
Indications for acute caesarean section among women
with epilepsy
Rationales for acute CSs among WWE were diverse.
Breech presentation was the main reason in four, pro-
longed cervix opening time in four and one had a
tonic-clonic seizure during labour. Combinations of
factors were reported in the rest (breech presentation,
failure to progress, asphyxia and rupture of placenta).
There were twice as many planned CSs before delivery
in the healthy group than in the epilepsy group (6%
vs. 3%, data not shown).
Pregnancy and obstetric complications
Low birth weight in offspring was more frequent in
the epilepsy group than among controls (7.3% vs.
3.7%, P = 0.05, Table 2). There was a non-significant
tendency of more pre-term birth in the epilepsy and




(n = 16 783) P-value
Chronic disease
(n = 1345) P-valueb
Age (years) 28.8 (5.6) 29.3 (5.2) 0.29 30.3 (5.2) <0.01
BMI at start of pregnancy 24.2 (4.6) 24.7 (4.8) 0.24 25.4 (5.4) 0.03
Mean placenta weight (g) 683.2 (172.0) 699.0 (158.1) 0.30 691.6 (168.1) 0.62
Mother > 35 years (%) 15.5 16.6 0.74 22.2 0.10
Parity (primipara) (%) 44.5 41.7 0.55 41.4 0.52
Smoking at start of pregnancy (%) 34.6 22.9 <0.01 22.2 <0.01
Smoking at time of labour (%) 17.3 12.3 0.12 13.3 0.25
Pre-gestational diabetes (%) 0.0 0.6 0.43 2.2 0.12
Significance is indicated in bold. Data are given as mean (SD) unless otherwise stated. BMI, body mass index. aActive epilepsy according to




(n = 16 783) P-value
Chronic disease
(n = 1345) P-valuea
Acute CS 18.2 10.3 <0.01 12.9 0.12
Total CS 20.9 15.4 0.11 22.7 0.67
Oligohydramnios 10.0 7.8 0.39 8.5 0.60
Breech presentation 8.2 3.7 0.02 4.1 0.04
Pre-term 8.3 5.9 0.30 8.6 0.92
Induction 20.9 16.5 0.21 18.4 0.51
GDM 2.7 0.9 0.05 1.3 0.24
Pre-eclampsia 5.5 5.2 0.92 7.9 0.36
Previous CS 8.2 8.3 0.97 11.7 0.26
Birth weight < 2500 g 7.3 3.7 0.05 4.9 0.28
Significance is indicated in bold. Data are given as percentages. CS, caesarean section; GDM,
gestational diabetes mellitus; previous CS, CS once or more before index pregnancy.
aCompared with epilepsy group.
Table 2 Frequency of pregnancy and
obstetric complications in the epilepsy
group compared with the healthy group
and chronic disease group
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chronic disease groups compared with the healthy
women. Breech presentations occurred significantly
more often in the epilepsy group (8.2% vs. 3.7%,
P = 0.02, Table 2). Epilepsy, AED use and AED
polytherapy were significant risk factors for breech
presentation in bivariate logistic regression analysis
(OR, 2.29, 95% CI, 1.16–4.56; OR, 2.42, 95% CI,
1.17–5.03; OR, 5.13, 95% CI, 1.12–23.44; Table 4). In
multivariate logistic regression analysis controlling for
established risk factors for breech presentation (pre-
term delivery, oligohydramnios and low birth weight)
[12], AED polytherapy had OR, 5.37, 95% CI, 1.13–
25.57, use of AED had OR, 2.13, 95% CI, 0.97–4.68
and epilepsy had OR, 1.78, 95% CI, 0.81–3.90
(Table 4).
There were no significant differences regarding the
frequency of hydramnios, induction of labour or pre-
eclampsia. Vaginal bleeding during pregnancy was
more common in the chronic disease group (4.6% vs.
8.4% P = 0.03, data not shown). The frequency of
gestational diabetes was significantly higher in the epi-
lepsy group (Table 2).
Discussion
We found that WWE using AEDs during pregnancy
had increased rate of acute CS, breech presentation and
low birth weight, but that seizures during pregnancy
did not influence the complication rate. Increased risk
of emergency CS among WWE has been reported previ-
ously [4,5], but without information about seizure fre-
quency or comparison with women with other diseases.
Antiepileptic drugs are previously reported as risk
factors for intrauterine growth retardation [19, 23]. It
could be argued that low birth weight might be a con-
founding factor for acute CS in this study as it is a
factor that is also associated with breech presentation
[14] and breech presentation is associated with acute
CS. However, controlling for breech presentation and
low birth weight still left AEDs as an independent risk
factor for acute CS.
The trend of increased risk of acute CS in women
with lamotrigine is not due to seizures or maternal
age. In eight out of nine women, the lamotrigine
doses were increased due to fall in serum level. The
seizure frequency during pregnancy was much the
same as has been reported by others [10,11]. As
expected, seizures were most frequent among those
using polytherapy, probably reflecting more severe
epilepsy.
The mothers’ own preferences and the obstetricians’
concern regarding ‘high-risk labour’ are important rea-
sons for CS [7,13]. In-depth examination revealed mul-
tiple obstetric reasons for acute CS in WWE. As most
of the AEDs used in this study are sodium or calcium
channel blockers, one factor of possible importance
might be that uterine excitability is modulated by
sodium channels and calcium-channel blockers are used
as tocolytic drugs [24,25]. Reasons for increased acute
CS risk in WWE are probably multifactorial and use of
AEDs appears to be the most important epilepsy-
related risk factor. Low birth weight and breech presen-
tation are also associated with acute CS and AEDs may
contribute directly and indirectly.
Table 3 Predictors for acute caesarean section (CS) in the Oppland Perinatal Database (active epilepsy and healthy)
Acute CS
Bivariate (n > 16 022) Multivariate (n > 15 784) Multivariate (n > 15 784) Multivariate (n > 15 784)
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
Epilepsy 1.93 (1.19–3.14) <0.01 1.64 (0.88–3.06) 0.12
AED 2.23 (1.34–3.70) <0.01 2.00 (1.06–3.77) 0.03
LTG 3.07 (1.21–7.79) 0.02 2.48 (1.19–10.20) 0.02
Maternal age >35 years 1.48 (1.31–1.67) <0.001 1.29 (1.12–1.48) <0.001 1.29 (1.12–1.48) <0.001 1.29 (1.12–1.47) <0.001
Birth weight < 2500 g 7.33 (6.20–8.67) <0.001 7.11 (5.87–8.61) <0.001 7.11 (5.87–8.61) <0.001 7.14 (5.89–8.65) <0.001
Smoking at start 1.12 (1.00–1.26) 0.06
GDM 2.04 (1.37–3.05) <0.001 1.38 (0.89–2.16) 0.16 1.39 (0.89–2.16) 0.15 1.39 (0.89–2.18) 0.14
UW 0.67 (0.48–0.94) 0.02 0.72 (0.50–1.05) 0.09 0.72 (0.60–1.22) 0.09 0.72 (0.50–1.05) 0.09
OWOB 1.74 (1.57–1.94) <0.001 1.71 (1.53–1.92) <0.001 1.71 (1.53–1.92) <0.001 1.72 (1.53–1.92) <0.001
Previous CS 2.98 (2.60–3.42) <0.001 3.03 (2.60–3.52) <0.001 3.02 (2.60–3.52) <0.001 3.03 (2.60–3.52) <0.001
Breech presentation 6.72 (5.72–7.88) <0.001 6.20 (5.14–7.49) <0.001 6.19 (5.13–7.48) <0.001 6.21 (5.15–7.50) <0.001
Seizures 1.78 (0.92–3.42) 0.69 0.98– (0.36–2.63) 0.96 0.81 (0.32–2.42) 0.81 1.04 (0.42–2.55 0.94
Odds ratio (OR) and 95% confidence interval (CI) for acute CS. Logistic regression analysis, bivariate and multivariate models were used. Sig-
nificance is indicated in bold. Epilepsy (light shading): bivariate and multivariate controlling for risk factors. Use of antiepileptic drugs (AEDs)
for epilepsy (medium shading): bivariate and multivariate controlling for risk factors. Lamotrigine for epilepsy (dark shading): bivariate and
multivariate controlling for risk factors. GDM, gestational diabetes; LTG, lamotrigine; OWOB, overweight and obesity at start of pregnancy
[body mass index (BMI) > 25 kg/m2]; previous CS, CS once or more before index pregnancy; smoking at start, registered as smoker at start of
pregnancy; UW, underweight (BMI < 18.5 kg/m2).
© 2018 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
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In contrast to some studies [2,16] and in line with
others [18], we did not find increased rates of pre-eclamp-
sia or vaginal bleeding in WWE compared with controls.
Contrary to most other similar studies, our cohort
is thoroughly validated regarding epilepsy and
includes 95% of the WWE in the catchment area. The
study benefits from the detailed information about the
subjects’ epilepsy diagnoses, seizure types and fre-
quency, treatment and detailed obstetric information.
The inclusion of two reference groups consisting of
healthy women and women with other chronic condi-
tions is another advantage.
The main limitation of this study is the relatively low
number of WWE. Results from the subgroup analyses
should therefore be interpreted with caution. Those
with chronic diseases did not have their diagnoses vali-
dated, which prevented further analyses. Finally, WWE
may be monitored more closely during pregnancy.
However, as most obstetric factors analysed are rou-
tinely assessed, such surveillance bias seems unlikely.
We suggest that further studies investigate the pos-
sible impact of AEDs on pregnancy complications, by
comparing with those using AEDs for non-epilepsy
indications. A systematic study regarding the causes
for acute CS would also be warranted.
In this study, women with active epilepsy had
higher rates of acute caesarean deliveries, breech pre-
sentation and low birth weight in offspring. Our find-
ings emphasize the need for special interdisciplinary
healthcare for WWE during pregnancy.
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